OakChart

Enliven Therapeutics Inc

ELVNHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

51.19-0.01 (-0.02%)
2026-11-12 04:05 CET
Market cap
3,767.33 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-113.48 USD m
Free cash flow, TTM
-66.41 USD m
EPS diluted, TTM
-1.70
P/E
-
Compare

Price

ELVN against its 20, 50 and 200-day averages
2050200beatmiss
30.0040.0050.0060.003.3M6.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ELVNclose 51.1920-day 44.3050-day 46.86200-day 43.6051.1952w high

17.9% under the 52-week high of 62.32 on 5 Aug 2026. 52-week low 14.79 on 6 Jan 2026. Last 15 sessions, 28.0% high to low

Volume 0.58× normal · the line is the 50-bar volume average

Profile

ELVN
52-week range, 77% of the way up
14.7862.32

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

IndexRUT
Employees60
IPOMar 12, 2020
Beta0.31
ATR, 14d2.19
Rel volume0.58
Short float16.81%
Insider own16.82%
Inst own100.09%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.77B
Enterprise Value2.88B
Income-113.48M
Sales0.00M
Book/sh11.92
Cash/sh12.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees60
IPOMar 12, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.29
P/C4.26
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio45.95
Current Ratio45.95
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.70
EPS next Y-2.09
EPS next Q-0.46
EPS this Y6.19%
EPS next Y-21.81%
EPS next 5Y-12.84%
EPS past 3/5Y46.65% 33.56%
Sales past 3/5Y- -
EPS Y/Y TTM7.94%
Sales Y/Y TTM-
EPS Q/Q-9.46%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.19.62% -

Ownership

Insider Own16.82%
Insider Trans-10.12%
Inst Own100.09%
Inst Trans39.83%
ROA-16.35%
ROE-16.77%
ROIC-12.93%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2015.55%
SMA509.24%
SMA20017.40%
Trades-

Technical

Shs Outstand73.56M
Shs Float61.22M
Short Float16.81%
Short Ratio7.69
Short Interest10.29M
52W High62.32 -17.86%
52W Low14.78 246.23%
Volatility6.27% 4.86%
ATR (14)2.19
RSI (14)66.37
Beta0.31
Rel Volume0.58
Avg Volume1.34M
Volume781,083

Performance

Perf Week8.34%
Perf Month29.63%
Perf Quarter-11.83%
Perf Half Y17.52%
Perf YTD232.40%
Perf Year160.64%
Perf 3Y349.82%
Perf 5Y245.88%
Perf 10Y-
Recom1.13
Target Price73.85
Prev Close51.20
Price51.19
Change %-0.02%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 02, 2026InitiatedMMorgan StanleyOverweight$70+36.7%
Oct 01, 2026InitiatedJJP MorganOverweight$75+46.5%
Aug 18, 2026InitiatedWWilliam BlairOutperform
Aug 18, 2026InitiatedBBarclaysOverweight$78+52.4%
Jun 09, 2026InitiatedSStifelBuy$60+17.2%
May 12, 2026InitiatedGGuggenheimBuy$80+56.3%
Jun 16, 2025InitiatedGGoldmanBuy$37-27.7%
Dec 13, 2024InitiatedBBTIG ResearchBuy$42-18.0%
Sep 09, 2024InitiatedHH.C. WainwrightBuy$37-27.7%
Jun 11, 2024InitiatedRRobert W. BairdOutperform$32-37.5%

Peers

Mkt cap
TickerCompanyMkt cap
AAPGAscentage Pharma Group International ADR1.40B
ERASErasca Inc5.88B
TYRATyra Biosciences Inc1.44B
IDYAIdeaya Biosciences Inc3.16B
RLAYRelay Therapeutics Inc4.36B
KURAKura Oncology Inc687.66M
SNDXSyndax Pharmaceuticals Inc863.37M
NVSNovartis AG ADR293.47B
BDTXBlack Diamond Therapeutics Inc92.50M
TAKTakeda Pharmaceutical Co ADR66.58B

Insider trading

latest 14 of 98
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kunkel Lori AnneDirectorOct 30 '26Option Exercise12.4811,041137,78052,925Nov 03 05:21 PM
Hohl BenjaminCHIEF FINANCIAL OFFICEROct 19 '26Option Exercise14.856,01889,36744,018Oct 21 05:53 PM
Hohl BenjaminCHIEF FINANCIAL OFFICEROct 19 '26Sale38.486,018231,54638,000Oct 21 05:53 PM
Collins Helen LouiseCHIEF MEDICAL OFFICEROct 19 '26Option Exercise2.485,00012,40030,000Oct 21 05:51 PM
Collins Helen LouiseCHIEF MEDICAL OFFICEROct 19 '26Sale38.475,000192,34225,000Oct 21 05:51 PM
Collins Helen LouiseDirectorOct 19 '26Proposed Sale37.3215,000559,800Oct 19 04:16 PM
Garland J. ScottDirectorOct 01 '26Option Exercise15.4713,000201,11013,000Oct 05 04:57 PM
Garland J. ScottDirectorOct 01 '26Sale46.6713,000606,7190Oct 05 04:57 PM
JEFFREY GARLANDDirectorOct 01 '26Proposed Sale46.6713,000606,719Oct 01 04:02 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERSep 17 '26Option Exercise14.853,98259,13344,018Sep 21 05:23 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERSep 17 '26Sale50.356,018303,00338,000Sep 21 05:23 PM
Collins Helen LouiseCHIEF MEDICAL OFFICERSep 17 '26Option Exercise2.485,00012,40030,000Sep 21 05:22 PM
Collins Helen LouiseCHIEF MEDICAL OFFICERSep 17 '26Sale50.355,000251,75425,000Sep 21 05:22 PM
Hohl BenjaminOfficerSep 17 '26Proposed Sale49.1212,036591,208Sep 17 04:33 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M

News

latest 14 of 164

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.360-0.448-0.3600.000.0014
2026Q22026-08-05-0.490-0.387-0.4910.000.0010
2026Q12026-05-07-0.380-0.444-0.3760.000.008
2025Q42026-03-03-0.480-0.385-0.4770.000.018
2025Q32025-11-12-0.320-0.433-0.3250.000.009
2025Q22025-08-13-0.490-0.537-0.4860.000.009
2025Q12025-05-14-0.570-0.502-0.5700.000.008
2024Q42025-03-13-0.460-0.515-0.4650.010.009
2024Q32024-11-13-0.480-0.497-0.4800.000.008
2024Q22024-08-13-0.410-0.550-0.4150.000.006
2024Q12024-05-14-0.540-0.543-0.5410.000.004
2023Q42024-03-14-0.470-0.537-0.4710.000.003
2023Q32023-11-09-0.510-0.473-0.5060.000.004
2023Q22023-08-10-0.410-0.397-0.4080.00-3
2023Q12023-05-11-0.800-0.633-0.7950.000.003
2022Q32022-10-25-0.998-0.998-0.701-0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-9.929--5.4310.00-
2020FY-14.120-15.299-14.1380.000.00
2021FY-9.480-10.224-10.7280.000.00
2022FY-3.680-3.800-12.0550.000.00
2023FY-2.010-2.163-2.0140.000.00
2024FY-1.890-1.946-1.8910.000.00
2025FY-1.830-1.735-1.8300.000.01
2026FY--1.717--0.00
2027FY--2.091--0.01
2028FY--2.629--0.01
2029FY--2.969--38.65
2030FY--1.617--245.38

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-067000.000.000.00
2026Q4S2026-11-057000.000.000.00
2026Q4S2026-10-057000.000.000.00
2026Q4S2026-09-306000.000.000.00
2026Q4S2026-09-095000.000.000.00
2026Q4S2026-08-066000.000.000.00
2026Q4S2026-06-055000.000.000.00
2026Q4S2026-06-014000.000.000.00
2026Q4S2026-05-083000.000.000.00
2026Q4S2026-03-043000.000.000.00
2026Q4S2025-11-132000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00

Estimate history

EPS, annual0-2.624-5.431-14.138-10.728-12.055-2.014-1.891-1.83-1.6993
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.48-0.465-0.57-0.486-0.325-0.477-0.376-0.491-0.355
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual4.324.324.324.3873.4353.5741.29248.93659.4473.557
Period201720182019202020212022202320242025MRQ
Shares, quarterly47.25448.93649.03959.22659.26159.4460.8973.25273.557
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.080.260.320.300.210.120.100.030.00
Gross Profit-0.08-0.26-0.32-0.30-0.21-0.12-0.10-0.030.00
Selling, General and Administrative Excl. Other135.28119.39104.2483.2338.5824.6541.6024.0810.68
Research and Development98.8785.5980.4664.2830.8120.3632.1519.018.24
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-135.36-119.66-104.55-83.53-38.79-24.76-41.70-24.12-10.68
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.00-0.870.000.000.000.00--
Net Income Before Taxes-113.48-103.69-88.79-71.58-37.66-24.74-41.36-23.46-11.34
Income Taxes0.000.000.230.000.000.000.000.000.00
Consolidated Net Income-113.48-103.69-89.02-71.58-37.66-24.74-41.36-23.46-11.34
Net Income From Continuing Operations-113.48-103.69-89.02-71.58-37.66-24.74-41.36-23.46-11.34
Net Income-113.48-103.69-89.02-71.58-37.66-24.74-49.22-23.46-11.34
EPS (Recurring)-1.46-1.83-1.90-2.01-12.05-10.73-14.14-5.43-2.62
EPS (Basic, Before Extraordinaries)-1.70-1.83-1.89-2.01-12.05-10.73-14.14-5.43-2.62
EPS (Diluted)-1.70-1.83-1.89-2.01-12.05-10.73-14.14-5.43-2.62
EBITDA-135.28-119.39-104.24-83.23-38.58-24.65-41.60-24.08-
Non-Operating Income (Expense)21.8815.9614.8911.951.130.020.340.65-0.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense41.6834.0215.9412.913.191.922.230.900.56
Price To Earnings Ratio---4.34-----
Shares Outstanding73.5659.4448.9441.293.573.444.394.324.32
Market Capitalization3,767.333,767.331,099.33570.37107.5159.15386.94370.65-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.050.060.080.070.08
Gross Profit-0.01-0.01-0.01-0.05-0.06-0.08-0.07-0.08
Selling, General and Administrative Excl. Other36.0337.2027.8134.2425.0328.5031.6226.82
Research and Development28.0128.9920.6721.2018.1621.4124.8220.64
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-36.05-37.21-27.82-34.28-25.10-28.58-31.69-26.90
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-27.70-32.48-23.63-29.67-20.15-25.34-28.54-23.18
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-27.70-32.48-23.63-29.67-20.15-25.34-28.54-23.18
Net Income From Continuing Operations-27.70-32.48-23.63-29.67-20.15-25.34-28.54-23.18
Net Income-27.70-32.48-23.63-29.67-20.15-25.34-28.54-23.18
EPS (Recurring)-0.36-0.49-0.38-0.48-0.32-0.49-0.57-0.46
EPS (Basic, Before Extraordinaries)-0.36-0.49-0.38-0.48-0.32-0.49-0.57-0.46
EPS (Diluted)-0.36-0.49-0.38-0.48-0.32-0.49-0.57-0.46
EBITDA-36.03-37.20-27.81-34.24-25.03-28.50-31.62-26.82
Non-Operating Income (Expense)8.344.724.204.624.953.253.153.72
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.0613.917.4012.317.187.726.805.34
Shares Outstanding73.5673.2560.8959.4459.2659.2349.0448.94
Market Capitalization3,767.333,625.492,344.18913.951,212.551,183.34964.411,099.33

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments462.62313.49253.2075.54110.0288.2228.917.389.67
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets12.264.6312.952.220.652.181.720.320.55
Total Current Assets474.88318.13266.1577.75110.6790.4130.627.7110.22
Net Property, Plant & Equipment0.420.461.061.520.950.350.440.000.00
Total Investments and Advances0.000.000.000.050.050.090.090.000.00
Intangible Assets---0.000.000.00-0.000.00
Deferred Tax Assets0.11--------
Other Assets0.877.174.653.981.650.002.140.000.00
Total Assets476.28325.76271.8783.30113.3390.8433.307.7110.22
Short Term Debt Incl. Current Port. of LT Debt0.400.000.340.320.160.000.000.000.00
Accounts Payable2.161.340.533.442.521.971.660.910.43
Other Current Liabilities14.0114.5725.035.953.074.282.540.920.40
Total Current Liabilities16.5715.9125.899.715.756.254.201.830.83
Long Term Debt0.000.000.000.000.000.000.000.000.66
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.11--------
Other Liabilities0.000.000.070.660.710.160.180.000.00
Total Liabilities16.6815.9125.9610.376.476.414.381.831.49
Non-Equity Reserves0.000.000.000.000.000.0077.7632.1924.27
Preferred Stock - Carrying Value0.000.000.00149.75149.750.000.000.000.00
Common Equity459.60309.85245.91-76.83-42.8984.44-48.85-26.32-15.53
Total Shareholders Equity459.60309.85245.9172.92106.8684.44-48.85-26.32-15.53
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity459.60309.85245.9172.92106.8684.44-48.85-26.32-15.53
Total Liabilities & Stockholders Equity476.28325.76271.8783.30113.3390.8433.307.7110.22
Book Value Per Share7.736.335.96-21.52-12.4919.25-11.31-6.09-3.60
Tangible Book Value Per Share7.736.335.96-21.52-12.4919.25-11.31-6.09-3.60
Full-Time Employees606246-412716--
Price to Book Ratio4.293.692.181.880.694.583.91--
Return on Assets-25.86-29.79-40.31-42.57-24.23-66.63-114.45-126.47-
Return on Equity-26.95-32.04-44.90-47.39-25.87-232.44---
Return on Invested Capital-22.56-28.73-29.11-51.65-23.15-48.98---
Quick Ratio28.6619.9910.288.0019.2414.477.294.2112.38
Current Ratio28.6619.9910.288.0019.2414.477.294.2112.38

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-113.48-103.69-89.02-71.58-37.66-24.74-41.36-23.46-11.34
Depreciation0.080.260.320.300.210.120.100.03-
Other Funds (Non Cash)42.0634.2520.068.624.931.922.350.881.32
Funds from Operations-71.34-69.18-68.65-62.67-32.52-22.70-38.91-22.55-10.01
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.13-1.12-4.541.400.443.571.510.671.24
Cash from Operating Activities-66.22-70.30-73.19-61.27-32.08-19.13-37.40-21.88-8.78
Capital Expenditures-0.19-0.16-0.04-0.15-0.61-0.19-0.02-0.140.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.210.210.000.000.000.000.000.000.00
Purchase or Sale of Investments-360.35-173.90-36.83-148.260.000.00-16.70-23.920.00
Purchase of Investments-747.49-446.79-350.74-268.260.000.00-64.20-23.920.00
Sale Or Maturity of Investments387.14272.90313.91120.000.000.0047.500.000.00
Other Uses0.000.00-9.130.000.000.000.000.000.00
Other Sources0.000.0010.000.000.000.000.000.000.00
Cash from Investing Activities-360.33-173.84-36.00-148.41-0.61-0.19-16.72-24.060.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock476.48218.87133.16161.20-1.80-1.0296.8845.586.49
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock476.48218.87133.16161.20-1.80-1.0296.8845.586.49
Proceedsfrom Stock Options0.450.40129.53160.80-1.80-1.0295.8645.586.49
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-2.000.00
Change in Long Term Debt0.000.000.000.000.000.000.00-2.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-2.000.00
Net Financing Active Other Cash Flow0.000.000.0073.080.000.000.000.000.00
Other Financing Activities Uses0.000.000.00-8.740.000.000.000.000.00
Cash from Financing Activities476.48218.87133.16234.29-1.80-1.0296.8843.586.49
Net Change in Cash49.94-25.2723.9824.61-34.49-20.3442.76-2.36-2.29
Free Cash Flow-66.41-70.46-73.24-61.42-32.69-19.32-37.42-22.02-8.78
Preferred Dividends (Cash Flow)-0.000.000.00-0.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments884.35895.15452.40462.62477.56490.50
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets10.4012.1810.7412.265.125.12
Total Current Assets894.76907.34463.14474.88482.68495.62
Net Property, Plant & Equipment1.511.640.310.420.871.03
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---0.11--
Other Assets0.961.241.410.877.327.24
Total Assets897.23910.22464.85476.28490.88503.89
Short Term Debt Incl. Current Port. of LT Debt0.510.600.300.400.390.38
Accounts Payable2.730.371.642.161.432.35
Other Current Liabilities16.2313.199.5414.0112.8312.48
Total Current Liabilities19.4714.1611.4916.5714.6515.21
Long Term Debt0.810.910.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.11--
Other Liabilities0.000.000.000.000.100.20
Total Liabilities20.2815.0711.4916.6814.7515.41
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity876.95895.15453.37459.60476.12488.47
Total Shareholders Equity876.95895.15453.37459.60476.12488.47
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity876.95895.15453.37459.60476.12488.47
Total Liabilities & Stockholders Equity897.23910.22464.85476.28490.88503.89
Book Value Per Share11.9212.227.457.738.038.25
Tangible Book Value Per Share11.9212.227.457.738.038.25
Full-Time Employees656761606563
Price to Book Ratio4.296.825.071.922.483.41
Return on Assets-16.35-14.98-25.74-25.86-24.41-24.12
Return on Equity-16.77-15.31-26.64-26.95-25.43-25.26
Return on Invested Capital-3.16-3.63-5.21-6.45-4.23-5.19
Quick Ratio45.9564.0740.3228.6632.9532.58
Current Ratio45.9564.0740.3228.6632.9532.58

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-27.70-32.48-23.63-29.67-20.15-25.34
Depreciation0.010.010.010.050.060.08
Other Funds (Non Cash)7.1914.557.7612.566.967.88
Funds from Operations-20.50-17.93-15.86-17.06-13.12-17.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital7.95-0.60-3.431.22-0.160.31
Cash from Operating Activities-12.55-18.53-19.29-15.84-13.28-17.06
Capital Expenditures-0.09-0.100.000.000.00-0.14
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.210.000.00
Purchase or Sale of Investments26.42-441.4742.5312.17-4.06-183.45
Purchase of Investments-45.97-560.16-65.84-75.52-71.86-240.19
Sale Or Maturity of Investments72.40118.69108.3687.6967.8056.74
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities26.33-441.5742.5312.38-4.06-183.59
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.39463.4210.050.62-0.37218.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.39463.4210.050.62-0.37218.38
Proceedsfrom Stock Options0.000.350.000.10-0.120.43
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.39463.4210.050.62-0.37218.38
Net Change in Cash16.163.3233.29-2.84-17.7017.73
Free Cash Flow-12.65-18.63-19.29-15.84-13.28-17.20

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.81%10.3M61.2M1.35M
2026-10-1515.31%9.3M61.0M1.16M
2026-09-3016.99%10.4M61.0M1.11M
2026-09-1514.14%8.6M61.0M1.23M
2026-08-3114.18%8.6M60.6M1.43M
2026-08-1413.62%8.3M60.6M1.40M
2026-07-3113.55%8.2M60.2M1.30M
2026-07-1514.75%8.7M58.7M1.32M
2026-06-3015.11%8.5M56.4M1.39M
2026-06-159.78%5.4M55.5M1.30M
2026-05-2911.10%5.2M47.0M1.08M
2026-05-1510.97%5.1M46.7M1.09M
2026-04-3011.84%5.3M44.6M1.12M
2026-04-1512.06%5.4M44.6M1.16M
2026-03-3113.88%6.1M43.6M1.32M
2026-03-1318.83%8.2M43.6M1.04M
2026-02-2718.29%8.0M43.6M1.03M
2026-02-1318.66%8.1M43.3M1.00M
2026-01-3018.10%7.9M43.5M1.01M
2026-01-1521.08%9.2M43.5M906.14K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call30.0019.5024.000.003.7610.000.000.884-0.3400.016
call35.0014.5019.008.503.0591.000.000.852-0.3170.018
call40.009.4013.301.852.32255.000.000.809-0.2840.022
call45.004.908.503.001.63645.000.000.732-0.2600.026
call50.001.054.702.251.2931020.000.590-0.2030.031
call55.000.002.150.621.1351227.000.378-0.1970.030
call60.000.000.850.101.07290.007.000.194-0.1340.022
call65.000.001.700.001.1570.000.000.109-0.0980.015
call70.000.001.700.751.0181.000.000.033-0.0340.006
call75.000.002.300.001.2010.000.000.029-0.0360.005
call80.000.002.300.002.1180.000.000.118-0.1890.016
put30.000.002.300.113.4835.000.00-0.102-0.2800.014
put35.000.002.300.852.7251.000.00-0.130-0.2600.017
put40.000.002.300.042.05110.000.00-0.170-0.2330.020
put45.000.002.601.341.39234.000.00-0.240-0.1930.025
put50.000.102.701.441.04725.0015.00-0.410-0.1970.031
put55.002.456.000.001.1660.000.00-0.622-0.1910.030
put60.006.7010.300.001.3620.000.00-0.806-0.1270.022
put65.0011.5015.600.001.8350.000.00-0.840-0.1460.019
put70.0016.5021.100.002.1000.000.00-0.859-0.1600.018
put75.0021.5025.800.002.3690.000.00-0.873-0.1710.017
put80.0026.5031.100.002.6100.000.00-0.882-0.1800.016

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-163Initial statement of beneficial ownership of securities2026-10-14SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-17144Filing for proposed sale of securities under Rule 144.SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-24SCHEDULE 13D/ASEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.03M3
2026-0900554.76K2
2026-080010.21M3
2026-07001.09M3
2026-060052.51M5
2026-0500198.97K1
2026-0400238.35K1
2026-03003.04M5
2026-02001.36M3
2026-01005.74M7
2025-1200224.28K2
2025-1100667.93K3

Institutional holders

Manager% owned
FMR LLC14.78%
ORBIMED ADVISORS LLC9.49%
Polar Capital Holdings Plc9.00%
BlackRock, Inc.6.10%
Vestal Point Capital, LP5.60%
Commodore Capital LP4.58%
PRICE T ROWE ASSOCIATES INC /MD/4.06%
VANGUARD CAPITAL MANAGEMENT LLC3.60%
CITADEL ADVISORS LLC2.90%
Fairmount Funds Management LLC2.60%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.64%
Fidelity Small Cap Growth Fund1.75%
Select Health Care Portfolio1.75%
iShares Russell 2000 ETF1.56%
T. Rowe Price New Horizons Fund, Inc.1.13%
Strategic Advisers Fidelity U.S. Total Stock Fund1.01%
Fidelity Advisor Health Care Fund0.94%
T. Rowe Price Health Sciences Fund, Inc.0.91%
Select Biotechnology Portfolio0.84%
Fidelity Stock Selector Small Cap Fund0.81%

OakChart. ELVN. Cached 15 minutes.